These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 12379094)

  • 1. Summaries for patients. Short-course treatment for latent tuberculosis is associated with more frequent liver injury than long-course treatment is.
    Ann Intern Med; 2002 Oct; 137(8):I32. PubMed ID: 12379094
    [No Abstract]   [Full Text] [Related]  

  • 2. The best approach to reintroducing tuberculosis treatment after hepatotoxicity is still open to debate.
    Chang KC; Leung CC
    Clin Infect Dis; 2010 Aug; 51(3):366-7; author reply 367-8. PubMed ID: 20597681
    [No Abstract]   [Full Text] [Related]  

  • 3. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
    Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
    Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrazinamide-induced sideroblastic anemia.
    Colucci G; Silzle T; Solenthaler M
    Am J Hematol; 2012 Mar; 87(3):305. PubMed ID: 21818765
    [No Abstract]   [Full Text] [Related]  

  • 5. Gynaecomastia during antituberculosis chemotherapy with isoniazid.
    Dixit R; Sharma S; Nawal CL
    J Assoc Physicians India; 2008 May; 56():390-1. PubMed ID: 18700651
    [No Abstract]   [Full Text] [Related]  

  • 6. [Scrofuloderma with hypersensitivity to rifampicin and pyrazinamide, treated with a combination therapy including ofloxacin].
    Belghith I; Badri T; Zaiem A; Benmously R; Mokhtar I
    Presse Med; 2012 Apr; 41(4):437-9. PubMed ID: 22000406
    [No Abstract]   [Full Text] [Related]  

  • 7. Effectiveness and safety of the schedules of short and long term treatment for tuberculous meningoencephalitis at two hospitals of Lima--Peru.
    Morales S; Ramos W; Vílchez R; Pérez J; Alvarado M
    Neurologia; 2011 May; 26(4):220-6. PubMed ID: 21163196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-tuberculosis chemotherapy and management of adverse reactions].
    Kuwabara K
    Nihon Rinsho; 2011 Aug; 69(8):1389-93. PubMed ID: 21838035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications.
    Guiastrennec B; Ramachandran G; Karlsson MO; Kumar AKH; Bhavani PK; Gangadevi NP; Swaminathan S; Gupta A; Dooley KE; Savic RM
    Clin Pharmacol Ther; 2018 Oct; 104(4):733-741. PubMed ID: 29247506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors.
    Bouazzi OE; Hammi S; Bourkadi JE; Tebaa A; Tanani DS; Soulaymani-Bencheikh R; Badrane N; Bengueddour R
    Pan Afr Med J; 2016; 25():167. PubMed ID: 28292129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
    Sun HY; Huang YW; Huang WC; Chang LY; Chan PC; Chuang YC; Ruan SY; Wang JY; Wang JT
    Tuberculosis (Edinb); 2018 Jul; 111():121-126. PubMed ID: 30029896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Adherence for 12 Weekly Doses of Isoniazid and Rifapentine for Pediatric Tuberculosis Infection.
    Cruz AT; Starke JR
    Pediatr Infect Dis J; 2016 Jul; 35(7):811-3. PubMed ID: 27088582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy.
    Namasivayam S; Maiga M; Yuan W; Thovarai V; Costa DL; Mittereder LR; Wipperman MF; Glickman MS; Dzutsev A; Trinchieri G; Sher A
    Microbiome; 2017 Jul; 5(1):71. PubMed ID: 28683818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Latent tuberculosis in childhood: tolerability of two different therapeutic approaches.
    Tersigni C; Venturini E; Cordola C; Piccini P; Bianchi L; Montagnani C; Sollai S; Chiappini E; de Martino M; Galli L
    Expert Rev Anti Infect Ther; 2018 Apr; 16(4):359-365. PubMed ID: 29465259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection.
    Pina JM; Clotet L; Ferrer A; Sala MR; Garrido P; Salleras L; Domínguez A
    Respir Med; 2013 May; 107(5):768-77. PubMed ID: 23490222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review.
    Assefa Y; Assefa Y; Woldeyohannes S; Hamada Y; Getahun H
    Eur Respir J; 2018 Jul; 52(1):. PubMed ID: 29748305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance.
    Reves R; Heilig CM; Tapy JM; Bozeman L; Kyle RP; Hamilton CD; Bock N; Narita M; Wing D; Hershfield E; Goldberg SV;
    Int J Tuberc Lung Dis; 2014 May; 18(5):571-80. PubMed ID: 24903795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.
    Menzies D; Long R; Trajman A; Dion MJ; Yang J; Al Jahdali H; Memish Z; Khan K; Gardam M; Hoeppner V; Benedetti A; Schwartzman K
    Ann Intern Med; 2008 Nov; 149(10):689-97. PubMed ID: 19017587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
    Sharma SK; Singla R; Sarda P; Mohan A; Makharia G; Jayaswal A; Sreenivas V; Singh S
    Clin Infect Dis; 2010 Mar; 50(6):833-9. PubMed ID: 20156055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ascites by peritoneal tuberculosis].
    de Escalante Yangüela B; Aibar Arregui M; Sáenz Abad D; Torrubia Pérez CB
    An Med Interna; 2007 May; 24(5):253-4. PubMed ID: 17929388
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.